Form 4: Crinetics Pharmaceuticals CEO Richard Struthers Reports Stock and Option Transactions
SEC Form 4
Richard Scott Struthers, CEO of Crinetics Pharmaceuticals, reports acquisition of stock and options, including restricted stock units and stock options, as per Form 4 filing.
Summary
- Richard Scott Struthers, the President & CEO of Crinetics Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
- On February 20, 2025, Struthers acquired 89,000 shares of Common Stock at $0 and 313,000 stock options with an exercise price of $36.86.
- Following the reported transactions, Struthers directly owns 346,485 shares of Common Stock.
- Struthers also indirectly owns shares through family trusts: 570,805 shares through Family Trust 1, 110,000 shares through Family Trust 2, 110,000 shares through Family Trust 3, 100,000 shares through Family Trust 4, and 1,000 shares through a spouse.
- The stock options vest in 48 equal monthly installments starting February 20, 2025, and expire on February 19, 2035.
- The restricted stock units vest 25% annually beginning on March 15, 2026.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard regulatory filing detailing stock and option transactions. The CEO's acquisition could be seen as a positive, but it's not definitive.
Positives
- The acquisition of stock and options by the CEO could be interpreted as a positive sign of confidence in the company's future prospects.
Future Outlook
The document does not contain explicit forward-looking statements, but the vesting schedules for the stock options and restricted stock units suggest a multi-year commitment from the CEO.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders. The details of the transactions themselves are specific to the individual and the company.
Stakeholder Impact
- Shareholders may view the CEO's stock and option acquisitions as a sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 02/20/2025 | Date of earliest transaction: Acquisition of Common Stock and Stock Options. |
| 02/20/2025 | Vesting commencement date for stock options. |
| 02/24/2025 | Date of Form 4 signature. |
| 03/15/2026 | Vesting start date for restricted stock units (25% annually). |
| 02/19/2035 | Expiration date for stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.